MXPA04000293A - Inhibidores de serina proteasa biciclica de puente. - Google Patents

Inhibidores de serina proteasa biciclica de puente.

Info

Publication number
MXPA04000293A
MXPA04000293A MXPA04000293A MXPA04000293A MXPA04000293A MX PA04000293 A MXPA04000293 A MX PA04000293A MX PA04000293 A MXPA04000293 A MX PA04000293A MX PA04000293 A MXPA04000293 A MX PA04000293A MX PA04000293 A MXPA04000293 A MX PA04000293A
Authority
MX
Mexico
Prior art keywords
serine protease
bridged bicyclic
compounds
protease inhibitors
relates
Prior art date
Application number
MXPA04000293A
Other languages
English (en)
Inventor
Farmer Luc
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MXPA04000293A publication Critical patent/MXPA04000293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invencion se relaciona con compuestos peptidomimeticos que inhiben la actividad de serina proteasa, en particular la actividad de la proteasa NS3-NS4A del virus de hepatitis C. como tales, actuan al interferir con ciclo vital del virus de hepatitis C y tambien son utiles como agentes antivirales. Los compuestos de esta invencion tienen una entidad biciclica de puente en la posicion P2. La invencion se relaciona ademas con composicisnes que comprenden estos compuestos ya sea para uso en vivo o para la administracion a un paciente que padece de infeccion por HCV. La invencion tambien se relaciona con los metodos para tratar una infeccion por HCV en un paciente al administrar una composicion que comprende un compuesto de esta invencion.
MXPA04000293A 2001-07-11 2002-07-11 Inhibidores de serina proteasa biciclica de puente. MXPA04000293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30461501P 2001-07-11 2001-07-11
US32271401P 2001-09-17 2001-09-17
PCT/US2002/022027 WO2003006490A1 (en) 2001-07-11 2002-07-11 Bridged bicyclic serine protease inhibitors

Publications (1)

Publication Number Publication Date
MXPA04000293A true MXPA04000293A (es) 2004-05-04

Family

ID=26974129

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000293A MXPA04000293A (es) 2001-07-11 2002-07-11 Inhibidores de serina proteasa biciclica de puente.

Country Status (15)

Country Link
US (1) US6909000B2 (es)
EP (1) EP1404704B9 (es)
JP (1) JP4455056B2 (es)
KR (1) KR100926244B1 (es)
CN (1) CN100402549C (es)
AT (1) ATE349463T1 (es)
CA (1) CA2449504A1 (es)
DE (1) DE60217114T2 (es)
ES (1) ES2279879T3 (es)
HK (1) HK1065322A1 (es)
IL (2) IL159087A0 (es)
MX (1) MXPA04000293A (es)
NO (1) NO20040127L (es)
NZ (1) NZ530000A (es)
WO (1) WO2003006490A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129407A0 (en) 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
PT1268519E (pt) * 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1441720B8 (en) * 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
WO2003087092A2 (en) 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
CA2532664A1 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4527722B2 (ja) * 2003-08-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
AR045769A1 (es) * 2003-09-18 2005-11-09 Vertex Pharma Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c)
US7365092B2 (en) 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
NZ546663A (en) * 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
PT1713823E (pt) * 2004-01-30 2010-02-02 Medivir Ab Inibidores da protease ns-3 da serina do hcv
CN1938332B (zh) * 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
KR20110137409A (ko) * 2004-03-12 2011-12-22 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한 방법 및 중간체
NZ594105A (en) 2005-07-25 2013-02-22 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
CN101273052B (zh) 2005-07-29 2016-01-13 爱尔兰詹森科学公司 丙型肝炎病毒的大环抑制剂
CN101282978B (zh) 2005-07-29 2012-07-11 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
CN101277950B (zh) 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
EP2364970A1 (en) 2005-08-19 2011-09-14 Vertex Pharmaceuticals Incorporated Processes and intermediates
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2007044893A2 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
RU2008123606A (ru) 2005-11-11 2009-12-20 Вертекс Фармасьютикалз, Инк (Us) Варианты вируса гепатита с
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US20080108632A1 (en) * 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
WO2008074035A1 (en) 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2379905T3 (es) * 2007-02-27 2012-05-04 Vertex Pharmceuticals Incorporated Co-cristales y composiciones farmacéuticas que los comprenden
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
AU2008219622A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JP2010528987A (ja) * 2007-05-03 2010-08-26 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
CL2008002549A1 (es) 2007-08-30 2010-09-03 Vertex Pharma Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
MX2010011306A (es) * 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
KR101670319B1 (ko) * 2009-09-15 2016-10-28 타이젠 바이오테크놀러지 컴퍼니 리미티드 Ｈｃｖ 프로테아제 저해제
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
US8476295B2 (en) * 2009-12-14 2013-07-02 Inspire Bridged bicyclic RHO kinase inhibitor compounds, composition and use
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP2013522202A (ja) 2010-03-09 2013-06-13 メルク・シャープ・エンド・ドーム・コーポレイション 縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
HUE036588T2 (hu) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Eljárások HCV kezelésére
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2254122A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
IL129407A0 (en) * 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
WO1998024806A2 (en) * 1996-12-06 1998-06-11 Cortech, Inc. Substituted oxadiazole, thiadiazole and triazole serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
DE69829381T2 (de) 1997-08-11 2006-04-13 Boehringer Ingelheim (Canada) Ltd., Laval Hepatitis c inhibitor peptide
WO1999050230A1 (en) 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
PT1268519E (pt) 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
JP4298289B2 (ja) 2000-07-21 2009-07-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Also Published As

Publication number Publication date
US6909000B2 (en) 2005-06-21
NZ530000A (en) 2007-03-30
CN1525979A (zh) 2004-09-01
KR20040018445A (ko) 2004-03-03
IL159087A0 (en) 2004-05-12
JP2005522409A (ja) 2005-07-28
ES2279879T3 (es) 2007-09-01
CN100402549C (zh) 2008-07-16
EP1404704A1 (en) 2004-04-07
ATE349463T1 (de) 2007-01-15
NO20040127L (no) 2004-03-11
IL159087A (en) 2009-08-03
KR100926244B1 (ko) 2009-11-12
DE60217114D1 (de) 2007-02-08
DE60217114T2 (de) 2007-10-25
HK1065322A1 (en) 2005-02-18
JP4455056B2 (ja) 2010-04-21
CA2449504A1 (en) 2003-01-23
WO2003006490A1 (en) 2003-01-23
EP1404704B1 (en) 2006-12-27
US20030119752A1 (en) 2003-06-26
EP1404704B9 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
MXPA04000293A (es) Inhibidores de serina proteasa biciclica de puente.
EP1441720B8 (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2006039488A3 (en) Hcv ns3-ns4a protease inhibition
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DE602004023924D1 (en) Ease-hemmer
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
WO2008106058A3 (en) Inhibitors of serine proteases
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
EA200300318A1 (ru) Пептидомиметические ингибиторы протеазы

Legal Events

Date Code Title Description
FG Grant or registration